Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on February 2, 2012, to announce its financial results for the fourth quarter and full year ended December 31, 2011. This filing primarily serves to furnish a press release detailing these results, which is attached as Exhibit 99.1. While the 8-K itself does not provide the specific financial figures, it directs investors to the press release for comprehensive information on the company's performance and financial condition for the period. Investors should review the referenced press release for details on revenue, profitability, and any forward-looking statements made by the company.
Key Highlights
- 1Edwards Lifesciences filed an 8-K on February 2, 2012, to report its Q4 and full-year 2011 financial results.
- 2The filing's primary purpose is to furnish a press release containing the financial results.
- 3The press release, dated February 2, 2012, is included as Exhibit 99.1 to the 8-K.
- 4This report does not contain the detailed financial results itself but refers investors to the exhibit for this information.
- 5The Chief Financial Officer, Thomas M. Abate, signed the report, indicating the accuracy of the disclosed information.
Frequently Asked Questions
The main purpose of this 8-K filing is to publicly announce and provide access to Edwards Lifesciences Corporation's financial results for the fourth quarter and the full year ended December 31, 2011, through an accompanying press release.
The actual financial results are detailed in the press release dated February 2, 2012, which is attached as Exhibit 99.1 to this 8-K filing. Investors should refer to Exhibit 99.1 for specific figures related to revenue, earnings, and other financial performance indicators.
This specific 8-K filing is focused on reporting historical financial results. Any strategic information, outlook, or forward-looking guidance would typically be found within the content of the press release (Exhibit 99.1) that is furnished with this report.